Welcome to our dedicated page for Trinity Biotech news (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech stock.
Trinity Biotech plc reports developments across its commercial-stage diagnostics and health technology business, including clinical laboratory products, point-of-care testing, diabetes management solutions, and wearable biosensor development. Its updates frequently cover the Premier Hb9210 HbA1c laboratory blood glucose monitoring platform, TrinScreen HIV testing, and the CGM+ continuous glucose monitoring program.
Company news also addresses specialty diagnostics initiatives such as EpiCapture prostate cancer testing and autoimmune biomarker work supported by its New York State Department of Health-certified reference laboratory. Other recurring topics include commercial operations in North America, manufacturing and cost-control actions under its Comprehensive Transformation Plan, ADS-based financing arrangements, trading updates, and Nasdaq listing-status notices.
Trinity Biotech (Nasdaq: TRIB) received a Nasdaq notice on Feb 19, 2026 saying it no longer meets the $15,000,000 minimum market value of publicly held shares (MVPHS) requirement under Nasdaq Rule 5450(b). The notice imposes a 180-calendar-day cure period ending Aug 18, 2026, during which the company must exceed $15,000,000 MVPHS for at least 10 consecutive business days to regain compliance. ADSs continue trading on the Nasdaq Global Select Market while the company evaluates options, including restoring market value, seeking transfer to The Nasdaq Capital Market if eligible, or appealing any delisting determination.
Trinity Biotech (Nasdaq: TRIB) received a Nasdaq notice on Feb 11, 2026 that it is not in compliance with Nasdaq Listing Rule 5450(a)(1) because its ADS closing bid price fell below $1.00 for the prior 30 consecutive business days.
The ADSs continue to trade on the Nasdaq Global Select Market. The company has 180 calendar days, until Aug 10, 2026, to regain compliance by achieving a $1.00 closing bid for at least 10 consecutive business days. If not cured, eligibility for a second compliance period requires meeting the MVPHS $15,000,000 and other listing standards for The Nasdaq Capital Market. Management is evaluating options to cure the deficiency and maintain listing.
Trinity Biotech (Nasdaq: TRIB) received final local regulatory approval to begin upstream manufacturing of its WHO‑prequalified Uni‑Gold™ HIV rapid test under an offshored and outsourced production model. This clearance completes the regulatory milestones needed to implement the new manufacturing approach.
The company says the transition to offshore upstream processes is expected to expand gross margins, improve working capital efficiency, and enhance scalability, supporting its Comprehensive Transformation Plan and long‑term financial profile. The approval follows WHO authorisation in November 2025.
Trinity Biotech (Nasdaq: TRIB) announced its Premier Hb9210™ HbA1c Analyser with the next-generation Buffer A Plus column system received the IFCC Gold Classification for 2026, making it the only HbA1c system worldwide to earn Gold status for 2026.
The certification reflects top-tier analytic precision and bias among >200 systems evaluated. Trinity highlights its ~$100 million cumulative investment in diabetes technologies and notes the global laboratory HbA1c market exceeds $2 billion, projected to surpass $3.5 billion by 2030. Senior commercial executives will attend the World Health Expo Feb 10–12, 2026 to discuss these advances.
Trinity Biotech (Nasdaq: TRIB) entered a series of agreements with Perceptive Advisors on Dec 23, 2025 to strengthen liquidity and extend its credit runway. Key elements include a $5 million additional term loan, up to $60 million elective equitization capacity, equity settlement mechanisms for $5 million of milestone payments and $7.5 million contingent acquisition consideration, and extension of the credit agreement maturity to Jan 15, 2027.
Perceptive may convert debt or payments into ADS at the greater of 97% of VWAP or a $1.03 floor, with conversions subject to a 9.9% beneficial ownership cap.
Trinity Biotech (Nasdaq: TRIB) received a 9 million-unit order for its WHO-prequalified TrinScreen HIV rapid test, with fulfillment planned in Q4 2025 and Q1 2026. The company reported Q3 2025 revenue $14.3M (+32% vs Q2 2025), gross profit $6.5M, gross margin rising to 45.2%, and Adjusted EBITDA $0.5M (vs -$2.1M in Q2 2025). Trinity cites WHO approval for outsourced manufacturing and expects further Adjusted EBITDA improvement in Q1–Q2 2026 as its Comprehensive Transformation Plan advances. Management promoted Paul Murphy to Interim CFO.
Trinity Biotech (Nasdaq: TRIB) announced expanded regulatory clearances and a wider rollout of its next‑generation high‑capacity HbA1c column system for the Premier Hb9210 analyzer, now available in more than 10 countries, including the United States.
The upgraded column offers up to 4x testing capacity, improved stability, reduced maintenance and a software update that automates routine tasks, which the company says supports higher throughput, recurring revenue potential and margin expansion in a global HbA1c market currently > $2B and forecast to exceed $3.5B by 2030.
Trinity Biotech (Nasdaq: TRIB) announced on November 18, 2025 that it received World Health Organization (WHO) approval for offshored and outsourced upstream manufacturing of its Uni-Gold™ HIV rapid test. The approval permits transitioning upstream production from in-house to outsourced offshore partners after ~two years of development. Management said the change is part of a broader transformation to streamline operations and is expected to improve gross margins, EBITDA and cashflow. The company plans to implement the new Uni-Gold™ manufacturing model in the coming months while retaining regulatory compliance and product integrity.
Trinity Biotech (Nasdaq: TRIB) announced a strategic collaboration with a bioinformatics partner to apply advanced analysis to clinical trial data for EpiCapture, its PCR-based epigenetic liquid biopsy for monitoring progression to high-grade prostate cancer.
The test, described as non-invasive, detects DNA methylation patterns and is in late-stage development aimed at regulatory approval and commercialization; a published study reported that EpiCapture correctly predicted all high-grade cancers when used with PSA. Trinity will leverage its New York State certified reference laboratory to support development and submission activities.
Trinity Biotech (Nasdaq: TRIB) on October 27, 2025 welcomed an indicated proposal from its largest investor and primary lender, Perceptive Advisors, to convert a portion of outstanding debt and other obligations into equity.
The company said the proposed equitization, if implemented, could strengthen the balance sheet, enhance financial flexibility and support its growth objectives while the company engages in discussions with Perceptive and other stakeholders. The release also reiterates standard forward-looking statement cautions and lists risks that could affect outcomes.